Clinical trial
Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR).
NCT03851263 is registered in ClinicalTrials.gov with ECRI bv as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-slice CT Scan Assessment of the Impact of PCSK9 Inhibition With Evolocumab on Coronary Perfusion in Patients With Reduced Coronary Fractional Flow Reserve (FFR).
- Lead sponsor
- ECRI bv
- Phase
- Phase 4
- Overall status
- Withdrawn
- Start date
- August 30, 2019
- Completion date
- February 24, 2023
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.